By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



111 Speen Street, Suite 306

Framingham  Massachusetts   01701  U.S.A.
Phone: 508-861-7709 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Alzheon


Company News
Alzheon Publishes New Analyses From Phase III Studies Showing Clinical Benefit Of Tramiprosate In Alzheimer’s Patients Who Are Carriers Of APOE4, The Major Genetic Risk Factor In Up To 65 Percent Of Alzheimer’s Patients 10/24/2016 10:56:07 AM
Alzheon To Present At Upcoming Asian Healthcare And Scientific Conferences 10/4/2016 11:31:00 AM
Alzheon To Present At Upcoming Investor Conferences 9/21/2016 11:18:11 AM
Alzheon To Present At Upcoming Industry Conferences 9/7/2016 1:38:18 PM
Alzheon Presents Positive Results Of ALZ-801 Clinical Studies That Lead To Advancement To Pivotal Phase III Study In Alzheimer's Patients With APOE4/4 Homozygous Genotype 7/25/2016 10:47:33 AM
Alzheon To Present At The 2016 JMP Securities Life Sciences Conference 6/16/2016 10:19:10 AM
Alzheon Appoints Dennis H. Langer, MD, JD, To Board Of Directors 3/11/2016 10:09:52 AM
Alzheon Wants Another Shot at Alzheimer's, Presents Data for Tweaked Phase III Studies on Once-Rejected Drug Tramiprosate 3/11/2016 6:13:58 AM
Top 20 Life Science Startups to Watch in the U.S. 1/26/2016 7:46:23 AM
What You Need to Know About Alzheon 12/17/2015 11:27:21 AM